Vivodyne is a biotechnology company developing a platform for preclinical drug discovery using lab-grown human organs, robotics, and AI to generate predictive human data before clinical trials.[1][2][5] It serves biopharma companies by testing thousands of tissues at scale, solving the high failure rate of drugs transitioning from animal models to human trials through ethical, human-relevant alternatives that improve accuracy, speed, and cost-efficiency.[3][5][6] With $38 million in seed funding in 2024 and $40 million in Series A in May 2025, Vivodyne shows strong growth, expanding to a 23,000-square-foot robotic facility in South San Francisco and partnering with leading pharma firms.[6][7]
Vivodyne was founded in 2020 by Dr. Andrei Georgescu, a bioengineering PhD from the University of Pennsylvania, and Associate Professor Dan Huh, emerging from Huh's organ-chip research group.[1][2][4] Georgescu's motivation stemmed from the poor translation between animal studies and human trials; his background includes sending lab-grown tissues to space with NASA and developing DNA synthesis chips.[4] The company launched its platform in 2021, licensing foundational US patents from Penn (US 11,066,633 and US 11,248,199), raised $4 million seed from Kairos Ventures, and earned Fast Company's #1 "Small but Mighty" company spot in 2022 for its automated tissue platform.[3]
Vivodyne rides the convergence of AI-driven biotech, organ-on-chip technology, and automation to address the ~90% preclinical-to-clinical failure rate in drug development.[1][3] Timing aligns with FDA pushes for human-relevant data, rising precision medicine demands, and ethical concerns over animal testing, amplified by post-2020 biotech funding surges.[5][7] Market forces like biopharma's need for faster, cheaper pipelines—amid $2.6B average drug development costs—favor its scalable, predictive platform, influencing the ecosystem by licensing tech to pharma giants and accelerating target discovery in oncology, fibrosis, autoimmune, and infectious diseases.[6][7]
Vivodyne's trajectory points to platform dominance in preclinical testing, with its new South San Francisco facility scaling output for broader biopharma adoption and internal pipelines.[7] Trends like generative AI in biology and regulatory human-data mandates will propel growth, potentially evolving it into a full-stack drug discovery leader or acquisition target. As biotech's "human data before the clinic" pioneer, Vivodyne positions investors and partners to capture value from more successful therapeutics pipelines.[6]
Vivodyne has raised $40.0M in total across 1 funding round.
Vivodyne's investors include Bison Ventures, Exor Ventures.
Vivodyne has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $40.0M Series A | Bison Ventures, Exor Ventures |
